Biosimilar user fee reauthorization negotiators couldn’t avoid disagreement during their first session, as two industry factions emerged over regulatory science issues.
Representatives of the Biosimilars Forum and the Association for Accessible Medicines (AAM) and its Biosimilars Council, which advocate for biosimilars and generic drugs, discussed a biosimilar regulatory science proposal during a 16 March
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?